# Lappaconitine

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/lappaconitine
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-19
**Evidence Score:** 4 / 10
**Category:** Compound
**Also Known As:** Lappaconitine, N-Deacetyllappaconitine, Aconitum alkaloid, Fuzi alkaloid, C18-diterpenoid alkaloid, LAP, 附子生物碱, Aconite alkaloid

## Overview

Lappaconitine is a diterpenoid alkaloid extracted from Aconitum sinomontanum that exerts analgesic and anti-inflammatory effects primarily through sodium channel blockade and suppression of [pro-inflammatory cytokine](/ingredients/condition/inflammation) cascades. It has been studied in both animal pain models and limited clinical settings, particularly for inflammatory conditions requiring cytokine modulation.

## Health Benefits

• Pain relief: Animal studies (PMID 41725249, 12928109) showed significant reduction in writhing episodes at 1-4 mg/kg doses in mice pain models (preliminary evidence)
• [Anti-inflammatory](/ingredients/condition/inflammation) effects: Clinical data showed reduced inflammatory markers (TNF-α, hs-CRP, IL-1, IL-6) when combined with CRRT in ICU sepsis patients (limited human evidence)
• Neuropathic pain management: Rat studies (PMID 29926144) demonstrated dose-dependent antiallodynia and antihyperalgesia with ED₅₀ values of 1.1-1.6 mg/kg (preliminary evidence)
• Opioid-sparing effects: Limited human data suggests 16 mg doses reduced morphine requirements and adverse reactions in combination therapy (preliminary clinical evidence)
• Antidiarrheal properties: Mouse studies showed prolonged diarrheal onset time in castor oil-induced models at 1-4 mg/kg doses (preliminary evidence)

## Mechanism of Action

Lappaconitine blocks voltage-gated sodium channels (Nav1.7, Nav1.8) on peripheral nociceptors, reducing action potential propagation and dampening pain signal transmission. It also suppresses NF-κB pathway activation, thereby downregulating transcription of [pro-inflammatory cytokine](/ingredients/condition/inflammation)s including TNF-α, IL-1β, and IL-6. Additionally, lappaconitine may interact with opioid receptors as a partial modulator, contributing to its central analgesic component observed in rodent models.

## Clinical Summary

Animal studies (PMID 41725249, PMID 12928109) demonstrated significant dose-dependent reductions in acetic acid-induced writhing episodes in mice at doses of 1–4 mg/kg, providing preliminary mechanistic evidence for analgesic activity. Clinical data examining lappaconitine combined with continuous renal replacement therapy (CRRT) showed measurable reductions in [inflammatory](/ingredients/condition/inflammation) markers including TNF-α, hs-CRP, IL-1, and IL-6, though these studies are limited in sample size and often confounded by co-interventions. The overall evidence base remains preliminary, with no large-scale randomized controlled trials establishing efficacy or optimal dosing in humans. Extrapolation of rodent dosing to human supplementation contexts is not currently supported by the available literature.

## Nutritional Profile

Lappaconitine is a diterpenoid alkaloid compound isolated from the roots of Aconitum sinomontanum and related Aconitum species. It is not a nutrient but a bioactive secondary metabolite characterized by a complex norditerpenoid skeleton, functioning as a sodium channel modulator with analgesic and [anti-inflammatory](/ingredients/condition/inflammation) properties at low milligram-per-kilogram doses.

## Dosage & Preparation

Animal studies used 1-8 mg/kg body weight orally or by injection. Limited human data suggests 16 mg as combination therapy showed best outcomes. No standardized human dosing guidelines are established. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Lappaconitine, like other aconitine-derived alkaloids, carries a cardiotoxicity risk at elevated doses, including potential for arrhythmias and QT interval prolongation, which necessitates caution during use. It may potentiate the effects of antiarrhythmic drugs (e.g., amiodarone, lidocaine) and other sodium channel blockers, creating dangerous additive effects on cardiac conduction. Concomitant use with anticoagulants or NSAIDs has not been formally studied but warrants caution given overlapping [inflammatory pathway](/ingredients/condition/inflammation) modulation. Lappaconitine is contraindicated in pregnancy due to the known teratogenic and toxic potential of Aconitum-derived alkaloids, and it should not be used without medical supervision.

## Scientific Research

Research consists primarily of preclinical animal studies including pain models in mice (PMID 41725249, 12928109) and [inflammatory](/ingredients/condition/inflammation) pain studies in rats (PMID 36295824, 9606904). Limited human clinical data exists, with one study showing efficacy at 16 mg doses for reducing morphine requirements, though comprehensive human RCTs and meta-analyses are lacking.

## Historical & Cultural Context

While lappaconitine is derived from Aconitum species used in traditional medicine, the research dossier does not provide specific historical or cultural context. Traditional uses and historical applications remain undocumented in the provided sources.

## Synergistic Combinations

Diclofenac sodium, loperamide, morphine (medical supervision required), CRRT therapy (clinical setting)

## Frequently Asked Questions

### What is lappaconitine used for?

Lappaconitine is primarily studied for pain relief and anti-inflammatory effects. Animal research at 1–4 mg/kg doses demonstrated significant reductions in pain response, while limited clinical data suggest it may reduce inflammatory markers such as TNF-α and IL-6, particularly when used alongside therapies like CRRT.

### How does lappaconitine relieve pain?

Lappaconitine blocks voltage-gated sodium channels, specifically Nav1.7 and Nav1.8 subtypes found on peripheral pain-sensing neurons, reducing the transmission of nociceptive signals to the brain. It may also interact with central opioid receptor pathways, contributing an additional analgesic effect observed in rodent writhing and hot-plate models.

### Is lappaconitine safe to take as a supplement?

Lappaconitine is derived from Aconitum plants and shares the cardiotoxic risk profile of aconitine-class alkaloids, including potential arrhythmia and QT prolongation at higher doses. It is not currently approved as a dietary supplement in most jurisdictions and should only be used under medical supervision; it is contraindicated in pregnancy and in individuals with pre-existing cardiac conditions.

### What plant does lappaconitine come from?

Lappaconitine is extracted from Aconitum sinomontanum, a perennial herb in the Ranunculaceae family native to mountainous regions of China. The root of this plant contains the highest concentration of lappaconitine and related norditerpenoid alkaloids, which require careful processing due to their inherent toxicity.

### Does lappaconitine reduce inflammation?

Yes, lappaconitine has demonstrated anti-inflammatory activity by suppressing the NF-κB signaling pathway, which controls transcription of cytokines including TNF-α, IL-1β, and IL-6. Clinical observations in patients receiving CRRT showed reduced levels of hs-CRP and these cytokines, though the evidence is preliminary and lappaconitine was not used as a standalone intervention in those studies.

### What does clinical research show about lappaconitine's effectiveness?

Animal studies demonstrate significant pain relief at doses of 1-4 mg/kg in mouse models, with preliminary evidence supporting its analgesic properties (PMID 41725249, 12928109). However, human clinical evidence remains limited, with most robust data coming from ICU sepsis studies showing reduced inflammatory markers (TNF-α, hs-CRP, IL-1, IL-6) when combined with CRRT treatment. Additional well-designed clinical trials are needed to establish efficacy and safety profiles in broader populations.

### Does lappaconitine interact with common medications?

Lappaconitine is an alkaloid compound that may interact with medications metabolized through hepatic pathways, though specific interaction data in humans remains limited. Given its potent pharmacological effects on pain and inflammation, concurrent use with other analgesics, anticoagulants, or immunosuppressants should be discussed with a healthcare provider. Direct clinical interaction studies are lacking and should be reviewed before combining with prescription medications.

### Who should avoid taking lappaconitine supplements?

Pregnant women, nursing mothers, and children should avoid lappaconitine due to insufficient safety data in these populations. Individuals with severe liver or kidney dysfunction should exercise caution, as the compound's metabolism and clearance may be compromised. Patients taking multiple medications or those with cardiovascular conditions should consult healthcare providers before use, given lappaconitine's potent pharmacological effects.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*